"目录号: HY-14541
Neuronal SignalingGPCR/G ProteinAutophagy-
Olanzapine(LY170053)是5-HT2和D2受体高亲和性拮抗剂。
相关产品
Cycloheximide-TAK-242-LY294002-3-Methyladenine-(+)-JQ-1-SB 203580-SP600125-U0126-Enzalutamide-Actinomycin D-Olaparib-Doxorubicin hydrochloride-Dorsomorphin dihydrochloride-Mitomycin C-Bortezomib-
生物活性
Description
Olanzapine(LY170053) is a high affinity for 5-HT2 serotonin and D2 dopamine receptor antagonist.IC50 Value:Target: 5-HT ReceptorOlanzapine is a thienobenzodiazepine that blocks especially the serontonin (5-hydroxytryptamine [5-HT]) 5-HT2A and the dopamine D2 receptors (Ki values are 4 and 11 nM respectively) as well as muscarinic (M1), histamine (H1), 5-HT2C, 5-HT3 to 5-HT6, adrenergic (α(l)), and D4 receptors. Atypical antipsychotic for the treatment of schizophrenia. Olanzapine displays anticholinergic properties.
Clinical Trial
Drexel University-National Institute of Mental Health (NIMH)
Autism
September 2004
Phase 2-Phase 3
University of Alabama at Birmingham-Mayo Clinic
Advanced Cancer
May 17, 2017
Phase 2-Phase 3
HealthPartners Institute
Headache
July 2016
University of Minnesota - Clinical and Translational Science Institute-Eli Lilly and Company
Borderline Personality Disorder
December 2005
Children's Hospital of Eastern Ontario
Eating Disorder
August 2010
Phase 3
The Hospital for Sick Children-Pediatric Oncology Group of Ontario
Chemotherapy-induced Nausea and Vomiting
March 2014
Phase 2
University of Michigan-Massachusetts General Hospital
Idiopathic Gastroparesis
January 2013
Dr. Reddy's Laboratories Limited
Fed
August 2011
Phase 1
Dr. Reddy's Laboratories Limited
Fasting
August 2011
Phase 1
Stanford University-Eli Lilly and Company
Bipolar Disorder
July 2005
Phase 4
University Hospital Freiburg
Therapy-resistant Depression
June 2005
Phase 3
University of North Carolina, Chapel Hill-Eli Lilly and Company
Psychotic Disorder-Schizophreniform Disorder-Schizophrenia-Schizoaffective Disorder-Mood Disorders With Psychotic Features
May 2005
Phase 1
University of Virginia
Alcohol Dependence
January 2007
Phase 2
Dr. Reddy's Laboratories Limited
Fed
November 2006
Phase 1
Dr. Reddy's Laboratories Limited
Fasting
November 2006
Phase 1
Hee Jun Kim-CJ HealthCare Corporation-Chung-Ang University Hosptial, Chung-Ang University College of Medicine
Chemotherapy-induced Nausea and Vomiting
July 2016
Charite University, Berlin, Germany-Eli Lilly and Company
Relapse Rate of a Major Depressive Episode-Safety of Olanzapine in Subjects With Major Depression
October 2007
Phase 3
Kunming Medical University-National Natural Science Foundation of China
Early-onset Schizophrenia
August 2015
Phase 4
Eli Lilly and Company
Schizophrenic Disorders-Schizoaffective Disorder
August 2004
Phase 3
Ottawa Hospital Research Institute-Eli Lilly and Company
Anorexia Nervosa
September 2000
Phase 2
Eli Lilly and Company
Schizophrenia
April 2006
Phase 3
Neuropsychiatric Research Institute, Fargo, North Dakota-Eli Lilly and Company-University of North Dakota
Weight Gain
July 2006
University Hospitals Cleveland Medical Center-Eli Lilly and Company
Bipolar Disorder
July 2002
Phase 3
M.D. Anderson Cancer Center
Advanced Cancer-Weight Loss
October 2006
Phase 1
Radboud University-GlaxoSmithKline
HIV Infections
November 2009
Phase 1
Orexigen Therapeutics, Inc
Schizophrenia-Schizoaffective Disorder-Schizophreniform Disorder
September 2008
Phase 2
Veterans Medical Research Foundation-Bristol-Myers Squibb
Diabetes
March 2009
Phase 4
Eli Lilly and Company
Depression, Bipolar
August 2007
Phase 3
Eli Lilly and Company
Bipolar I Disorder
February 2008
Phase 3
Indiana University
Chemotherapy Induced Nausea and Vomiting
February 2014
Phase 2
Seattle Institute for Biomedical and Clinical Research-Eli Lilly and Company
Schizophrenia-Schizoaffective Disorder-Bipolar Disorder-Obesity-Metabolic Syndrome
July 2007
National Taiwan University Hospital-Yu-Li Hospital
Schizophrenia-Schizoaffective Disorder-Agitation
July 2006
Phase 3
Northwell Health-Eli Lilly and Company
Anorexia Nervosa
June 2000
Phase 4
The Hospital for Sick Children
Vomiting in Infants and/or Children-Nausea-Hematopoietic System--Cancer
June 2017
Phase 2
New York State Psychiatric Institute-National Institute of Mental Health (NIMH)-Weill Medical College of Cornell University-University of Pittsburgh-Johns Hopkins University-University of Toronto
Anorexia Nervosa
August 2010
Duke University
Schizophrenia-Schizoaffective Disorder
April 2008
Phase 4
Rush University Medical Center
Nausea-Vomiting
November 2016
Phase 3
Michael Rickels-University of Pennsylvania-Monell Chemical Senses Center
Normal Non-fluency
August 2012
Phase 1
Harvard Medical School-National Institute of Mental Health (NIMH)-Dartmouth-Hitchcock Medical Center-Commonwealth Research Center, Massachusetts-Eli Lilly and Company
Schizophrenia
August 1998
Phase 4
The Mind Research Network
Alcohol Dependence
September 2002
Phase 3
China Medical University, China
Bipolar Disorder-Depression, Bipolar
January 2009
Phase 4
Kaohsiung Kai-Suan Psychiatric Hospital-Department of Health, Executive Yuan, R.O.C. (Taiwan)
Schizophrenia
January 2012
Phase 4
Eli Lilly and Company
Schizophrenia-Bipolar Disorder
June 2005
Phase 3
The New England Baptist Hospital
Delirium
January 2005
M.D. Anderson Cancer Center
Advanced Cancer
June 2005
Milton S. Hershey Medical Center-American Medical Association
Insulin Resistance-Diabetes Mellitus
August 2008
Eli Lilly and Company
Schizophrenia-Schizoaffective Disorder-Bipolar Disorder
March 2006
Phase 4
Jaime B Hyman-Icahn School of Medicine at Mount Sinai
Postoperative Nausea and Vomiting
January 2016
Phase 2
